 Liposomes are nanodrug delivery systems that have been successfully translated into real-time clinical applications since their first development in 1965 with extensive research being carried out in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. Clinically used products such as Doxyl, Ambisum, Depodur, etc. have contributed significantly to the healthcare sector with ongoing clinical trials on liposomes providing a detailed update on liposomal technologies and formulation aspects. This article was authored by Upendra Bulbic, Sindhidapulapudi, Nagavendra Komeneni, and others.